<DOC>
	<DOCNO>NCT02750306</DOCNO>
	<brief_summary>This study aim examine safety efficacy suvorexant ( MK-4305 ) improve sleep individual Alzheimer 's disease ( AD ) . The primary hypothesis study suvorexant superior placebo improve insomnia measure change baseline polysomnography ( PSG ) -derived total sleep time ( TST ) Week 4 .</brief_summary>
	<brief_title>Safety Efficacy Suvorexant ( MK-4305 ) Treatment Insomnia Participants With Alzheimer 's Disease ( MK-4305-061 )</brief_title>
	<detailed_description />
	<mesh_term>Alzheimer Disease</mesh_term>
	<mesh_term>Sleep Initiation Maintenance Disorders</mesh_term>
	<mesh_term>Suvorexant</mesh_term>
	<criteria>Diagnosis probable Alzheimer 's disease base either ) National Institute Aging Alzheimer 's Association ( NIAAA ) criteria b ) Diagnostic Statistical Manual Mental Disorders , 5th Edition , ( DSM5 ) criterion AD . Have DSM5 diagnosis insomnia ( e.g. , difficulty initiate maintain sleep , and/or early morning awakening inability return sleep least 3 night per week ≥ past 3 month prior study start , despite adequate opportunity sleep ) base investigator 's judgment subject 's sleep history , assess sleep item Insomnia Diagnostic Interview Sleep History assessment . Be willing stay overnight sleep laboratory must willing stay bed least 8 hour PSG test Regular bedtime 8 pm 1 willing maintain duration trial Be able willing wear activity/sleep watch wrist throughout day night Based investigator 's judgment participant : ) able speak , read , understand language trial staff inform consent form ; b ) posse ability respond verbally question , follow instruction , complete study assessment ; c ) able adhere dose visit schedule . Have reliable competent trial partner ( e.g. , spouse , family member , caregiver ) : ) Signs informed consent , trial explain , Screening assessment ; b ) Resides participant overnight close relationship participant ( defined daily facetoface contact , least 15 waking hour week least 3 month prior Visit 1 ) ; c ) Accompanies participant trial visit stay overnight sleep laboratory three PSG visit ; ) Assumes responsibility trial medication procedure ( e.g. , witness and/or help administer trial medication , assess compliance ) , completion sleep ediary morning , oversight activity/sleep watch worn throughout trial ; e ) Answers question regard trial partner 's sleep quality trial partner 's distress relate subject 's behavior . If female , childbearing potential indicated one following : reach natural menopause , define : ) ≥ 45 year age either : ≥ 12 month spontaneous amenorrhea OR ≥ 6 month spontaneous amenorrhea serum follicle stimulate hormone ( FSH ) level &gt; 40 IU/L determine central laboratory b ) hysterectomy ; c ) bilateral tubal ligation ; ) bilateral oophorectomy ( without hysterectomy ) great 6 week pass since surgery Be willing provide blood sample Apolipoprotein E ( APOE ) genotyping Resides nursing home ( similar institutional facility ) Has Modified Hachinski Ischemia Scale ( MHIS ) Score &gt; 4 Screening ( i.e. , evidence vascular dementia ) Has know history recent ( past ) stroke investigator 's opinion confound diagnosis either AD insomnia Has evidence clinically relevant neurological disorder disease study ( i.e. , probable AD ) Screening , include limited : vascular dementia , parkinsonism , frontotemporal dementia , Huntington 's disease , amyotrophic lateral sclerosis , multiple sclerosis , progressive supranuclear palsy , neurosyphilis , dementia Lewy body , type dementia , mental retardation , hypoxic cerebral damage , cognitive impairment due disorder , history head trauma loss consciousness either lead persistent cognitive deficit opinion investigator confound diagnosis either AD insomnia . Has history seizure epilepsy within last 5 year study start Has history diagnosis follow condition , opinion investigator : Narcolepsy Cataplexy ( familial idiopathic ) Circadian Rhythm Sleep Disorder Parasomnia include nightmare disorder , sleep terror disorder , sleepwalk disorder REM behavior disorder Significant degree sleeprelated Breathing Disorder ( i.e. , AHI &gt; 30 , and/or use Continuous Positive Airway Pressure ( CPAP ) Bilevel Positive Airway Pressure ( BIPAP ) ) Periodic Limb Movement Disorder Restless Legs Syndrome Primary Hypersomnia Excessive Daytime Sleepiness ( EDS ) characterize uncharacteristic chronic persistent sleepiness throughout day Has clinically significant movement disorder , akinesia , would affect activity/sleep watch differentiation sleep wakefulness In opinion investigator , difficulty sleep primarily due confound medical condition . NOTE : `` Medical Conditions '' may include chronic pain syndrome , chronic migraine , cardiac disease , nocturia ( &gt; 3 times/night ) , asthma , gastroesophageal reflux disease ( GERD ) , hot flash . Has evidence current episode major depression base investigator 's judgment . Major depression remission exclusionary . Has follow base clinician interview DSM5 criterion : Lifetime history bipolar disorder , psychotic disorder , posttraumatic stress disorder ; , A psychiatric condition require treatment prohibit medication ; , Other psychiatric condition , investigator 's opinion , would interfere subject 's ability participate study . Is imminent risk selfharm , base clinical interview response ColumbiaSuicide Severity Rating Scale ( CSSRS ) , harm others opinion investigator . Subjects must exclude report suicidal ideation intent , without plan method past 2 month suicidal behavior past 6 month . Has history alcoholism drug dependency/abuse within last 5 year study start Has recent history ( within 6 month prior Screening ) regular consumption ( 3 day per week ) either : More 2 alcoholic beverage per day alcohol consumption within 3 hour prior bedtime More &gt; 600 mg caffeine day ( e.g. , 4 standard 8ounce cup brew coffee , consumes caffeine 4pm ( 16:00 ) Consumes equivalent &gt; 15 cigarette day investigator confirm participant 's insomnia part result tobacco consumption ( e.g. , participant unable refrain smoking night , participant interrupt sleep smoke use tobacco product , participant require cigarette within 30 minute wake morning ) . Has history excessive daytime napping ( define 3 hour day 3 day week base trial partner estimate , average past 4 week ) . Has recent ongoing , uncontrolled , clinically significant medical condition major surgery participation trial would pose significant medical risk subject within 3 month study start , : condition include limited diabetes , hypertension , Human Immunodeficiency Virus ( HIV ) relevant infection , thyroid endocrine disease , Chronic Obstructive Pulmonary Disease ( COPD ) , delirium , congestive heart failure , angina , cardiac gastrointestinal disease , renal disease require dialysis . Note : control comorbid condition ( include diabetes , hypertension , heart disease , etc . ) exclusionary stable within three month study start . All concomitant medication , supplement , substance must keep stable medically possible trial . Urinary tract infection study start exclusionary adequately treat . Major surgery include limited abdominal , thoracic , cardiac orthopedic surgery , procedure require general anesthesia Has history hepatitis liver disease , opinion investigator , active within six month prior study start . Has know allergy hypersensitivity suvorexant formulation component Has history hypersensitivity idiosyncratic reaction three ( 3 ) chemical class drug , include prescription overthecounter medication . Has donate blood product phlebotomy &gt; 300 mL within 8 week study start , intend donate receive blood product participation study . History malignancy ≤5 year prior study start , except adequately treat basal cell squamous cell skin cancer , situ cervical cancer , localize prostate cancer , undergone potentially curative therapy evidence recurrence ≥ 3 year posttherapy , deem low risk recurrence her/his treat physician . Is pregnant , attempt become pregnant , nursing child Has Body Mass Index ( BMI ) &gt; 40 kg/m^2 Is currently participate participate study investigational compound device within 30 day sign informed consent</criteria>
	<gender>All</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>90 Years</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>